{"id":266,"date":"2020-11-30T11:20:30","date_gmt":"2020-11-30T15:20:30","guid":{"rendered":"http:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=266"},"modified":"2020-11-30T11:20:30","modified_gmt":"2020-11-30T15:20:30","slug":"hhs-oigs-special-fraud-alert-on-speaker-programs-by-pharma-and-device-companies","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2020\/11\/30\/hhs-oigs-special-fraud-alert-on-speaker-programs-by-pharma-and-device-companies\/","title":{"rendered":"HHS OIG\u2019s Special Fraud Alert on Speaker Programs by Pharma and Device Companies"},"content":{"rendered":"<p class=\"DMBdyTxt\">On November 16, 2020, the Department of Health and Human Services (HHS) Office of Inspector General (OIG)\u00a0issued\u00a0a Special Fraud Alert addressing speaker programs presented by pharmaceutical and medical device companies. Such programs, at which companies may pay physicians or other health care professionals (HCPs) for speeches or presentations about drugs and devices in addition to providing remuneration to attendees, are frequently sponsored by pharmaceutical and device companies seeking to provide education regarding their products. Highlighting what it called \u201cinherent fraud and abuse risks,\u201d OIG\u2019s Special Fraud Alert expressed concerns surrounding the offer or payment of remuneration from pharmaceutical and device companies to physicians or other HCPs associated with such programs.<\/p>\n<p class=\"DMBdyTxt\">To read the full text of this Duane Morris\u00a0<i>Alert<\/i>, please\u00a0<a href=\"https:\/\/www.duanemorris.com\/alerts\/hhs_oig_issues_rare_special_fraud_alert_addressing_speaker_programs_1120.html\" target=\"_blank\" rel=\"noopener noreferrer\">visit the firm website<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On November 16, 2020, the Department of Health and Human Services (HHS) Office of Inspector General (OIG)\u00a0issued\u00a0a Special Fraud Alert addressing speaker programs presented by pharmaceutical and medical device companies. Such programs, at which companies may pay physicians or other health care professionals (HCPs) for speeches or presentations about drugs and devices in addition to &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2020\/11\/30\/hhs-oigs-special-fraud-alert-on-speaker-programs-by-pharma-and-device-companies\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;HHS OIG\u2019s Special Fraud Alert on Speaker Programs by Pharma and Device Companies&#8221;<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[504,505,77,506],"ppma_author":[521],"class_list":["post-266","post","type-post","status-publish","format-standard","hentry","category-general","tag-duane-morris-alert","tag-medical-device-companies","tag-pharmaceutical","tag-physicians"],"authors":[{"term_id":521,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/266","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=266"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/266\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=266"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=266"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=266"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=266"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}